A Phase I/IIa multicenter dose-escalation study of subcutaneous intermittent interleukin-7 CYT107 in chronically HIV-infected pts with CD4 T-lymphocyte counts between 101-400 cells/mm(3) and plasma HIV RNA less than 1000 copies/ml after at least 12-m HAART.

Trial Profile

A Phase I/IIa multicenter dose-escalation study of subcutaneous intermittent interleukin-7 CYT107 in chronically HIV-infected pts with CD4 T-lymphocyte counts between 101-400 cells/mm(3) and plasma HIV RNA less than 1000 copies/ml after at least 12-m HAART.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2012

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms INSPIRE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2012 Results published in Clinical Infectious Diseases.
    • 23 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top